You are here

Programme at a Glance - 55th EASD Annual Meeting

Wednesday, 18 September 2019

 Joslin HallVilanova HallOchoa HallServet HallTrueta HallSerrano-Rios HallSols Hall
08:30
10:00
SGLT2 inhibitors for type 1 diabetes: clinical implicationsWhy is paediatric type 2 diabetes a more aggressive disease?Reducing hypoglycaemia in patients treated with insulinMetabolic surgery updateDiabetic retinopathy: looking beyond the eyesThe undervalued actors in metabolism: pancreatic alpha cells and glucagon 
10:15
11:45
OP 13OP 14OP 15OP 16OP 17OP 18 
12:00
13:00
Poster Event C (12:00 - 13:00, Poster Hall)
DECLARE study: call for actionThe St Vincent Declaration: 30 years onImeglimin: a first-in-class oral medication with a unique mechanism of action targeting mitochondrial bioenergetics   

EASD e-Learning: Introduction to diabetic complications

(12:00 - 13:30)

13:15
14:15
Vildagliptin Efficacy in combination with metfoRmIn For earlY treatment of T2DM (VERIFY)Dapagliflozin effects on biomarkers, symptoms and functional status in patients with heart failure and reduced ejection fraction with and or without diabetes: the DEFINE-HF trial   Beta cell replacement therapy for insulin-dependent diabetes
Poster Event D (13:15 - 14:15, Poster Hall)
14:30
16:00
OP 19OP 20OP 21OP 22OP 23OP 24

EUDF Symposium: Excellence, equity and efficiency in diabetes care

(14:00 - 16:00)

16:15
17:15
EASD-Novo Nordisk Foundation Diabetes Prize for Excellence     
17:30
18:30
EASD/ADA Symposium: Digital apps for diabetes treatment and prevention: opportunities and challengesNew directions for paediatric diabetes registriesRaising awareness about hypoglycaemia unawarenessNew insights into diabetic kidney diseaseDiabetes and neurodegenerative disease: What is the link?Exploring myths in diabetes 

 

Thursday, 19 September 2019

 Joslin HallVilanova HallOchoa HallServet HallTrueta HallSerrano-Rios HallSols HallMaimónides Hall
08:30
10:00
Incretin based medication: current state and future developmentsHyperglycaemia in pregnancy: treatment and risk for mother and childNew data from the Restoring Insulin Secretion (RISE) StudyDiabetologia Symposium: Developmental origin of diabetesIs type 2 diabetes produced by precocious senescence?Targeting liver may have an impact on glycaemia?  
10:15
11:45
OP 25OP 26OP 27OP 28OP 29OP 30  
12:00
13:00
Poster Event E (12:00 - 13:00, Poster Hall)
CONCLUDEUnique features and findings of the long-term REWIND (Researching cardiovascular Events with a Weekly INcretin in Diabetes) trial Innovative technologies in obesity and type 2 diabetes discovery and treatment  

EASD e-Learning: Pathogenesis and arresting type 1 diabetes

(12:00 - 13:30)

EFSD / AstraZeneca Mentorship Presentation

(12:30 - 14:00)

13:15
14:15
Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure (DAPA-HF)Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephRopathy In TYpe 2 diabetic patients with normoalbuminuria: (PRIORITY) studyResults and implications of CAROLINA (CARdiOvascular Safety of LINAgliptin) comparing linagliptin vs glimepiride   
Poster Event F (13:15 - 14:15, Poster Hall)
14:30
16:00
OP 31OP 32OP 33OP 34OP 35OP 36  
16:15
17:00

Induction of Honorary Members

54th Minkowski Lecture

       
17:15
18:15
Diabetes in primary careDialogue between clinical chemistry and diabetologyMichael Berger debate: The emphasis on sedentary behaviour as lifestyle intervention target is entirely warrantedReactive metabolites in mechanisms of insulin resistanceThe many faces of type 2 diabetesDiabetes and the brain: from mice to man  
18:15
20:15
      EUDF Evening Symposium: From concept to coalition.  National responses to the diabetes epidemic 

 

View the Industry Symposia Programme here.